A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs INCB 52793 (Primary) ; Gemcitabine; Itacitinib; Paclitaxel
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 18 Apr 2017 INCB052793 and itacitinib Combination Therapy is now added to the study which will be conducted into I/II phase. Also responce rate as a end-point is now added thus focus changed from AR to TU + AR.Thus additional changes in official title and inclusion-exclusion criteria
- 18 Apr 2017 Planned number of patients changed from 282 to 141.
- 18 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.